In prostate cancer (PCa), up to 50% of cases are characterized by TMPRSS2:ERG gene fusions, in which ERG expression is driven by the androgen-responsive TMPRSS2 promoter (5, 7, 8). This evidence concerns the gene ERG and prostate carcinoma.